Latest Pyrazines Stories
A typical dose of the medication Pyrazinamide, key to treating tuberculosis, may be too low because of modern-day physiques, U.S. researchers said. Lead author Dr. Tawanda Gumbo of the University of Texas Southwestern Medical Center in Dallas suggests today's TB dosage may not take into account the trend in some societies towards obesity. The researchers propose different doses are probably needed in different countries. What really drives the variability of this particular drug is patient...
The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques,UT Southwestern Medical Center researchers said. The finding, reported online and in the August edition of Antimicrobial Agents and Chemotherapy, is particularly important for those living in societies plagued by obesity, said Dr. Tawanda Gumbo, associate professor of internal medicine at UT Southwestern and the study's lead author."What really drives...
The Food and Drug Administration is tightening up on smoking cessation drugs, Chantix and Zyban, by requiring the drugs to be labeled with safety warnings over side effects including depression and suicidal thoughts.New regulations are based on reports of people experiencing depression or having suicidal thoughts while using the drug.The FDA is also requiring a study on Chantix and Zyban to fully understand the side effects of the drugs. Pfizer Inc., which makes Chantix, already has been...
Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most advanced clinical trial of single-agent carfilzomib demonstrating anti-cancer activity and progression-free survival in patients with relapsed and refractory multiple myeloma. Carfilzomib is the first...
Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American Society of Oncology (ASCO) in Orlando, Florida. Data from a Phase 1b study and an ongoing Phase 2 clinical trial of carfilzomib in relapsed patients with advanced solid tumors demonstrate promising...
Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations SOUTH SAN FRANCISCO, May 15 /PRNewswire/ -- Proteolix, Inc. today announced that data from clinical trials of carfilzomib in multiple myeloma and advanced solid tumors will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 29 - June 2, 2009 in Orlando, Florida. Carfilzomib is the first...
People with a likely history of depression who take varenicline (Chantix®) do not report more severe mood symptoms, medication side effects, or less success quitting smoking compared to people with no history of depression taking this drug.  The findings by Group Health, Free & Clear, and SRI International researchers are reported in a Journal of General Internal Medicine article published online (www.springerlink.com/content/77207452k3822r3v/). The National Cancer Institute...
New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced updated clinical results from an ongoing Phase 1/2 study of KRX-0401 (perifosine) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data, which was presented earlier today in a poster featured...
EUSAPharma (formerly Cytogen) Posts Positive Phase I Report from Trial of Quadramet in Combination with Velcade for the Treatment of Relapsed or Refractory Multiple Myeloma. LOS ANGELES, Feb. 11 /PRNewswire/ -- Quadramet (153 Samarium-lexidronam) is a radioactive medication that targets the bone, specifically bone cancer, and is used to treat pain caused by cancer that has metastasized or spread to the bone. Velcade (bortezomib) is approved for the treatment of multiple myeloma alone and...
WASHINGTON, Feb. 3 /PRNewswire-USNewswire/ -- Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade(R)), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being...
